6XFP

Crystal Structure of BRAF kinase domain bound to Belvarafenib

Summary for 6XFP

• Entry DOI: 10.2210/pdb6xfp/pdb
• Descriptor: Serine/threonine-protein kinase B-raf, 4-amino-N-{1-[(3-chloro-2-fluorophenyl)amino]-6-methylisoquinolin-5-yl}thieno[3,2-d]pyrimidine-7-carboxamide, CHLORIDE ION, ... (4 entities in total)
• Functional Keywords: braf belvarafenib, signaling protein
• Biological source: Homo sapiens (Human)
• Total number of polymer chains: 1
• Total formula weight: 33524.27

Authors

Yin, J.,Sudhamsu, J. (deposition date: 2020-06-16, release date: 2021-03-10, Last modification date: 2023-10-18)

• Primary citation: Yen, I.,Shanahan, F.,Lee, J.,Hong, Y.S.,Shin, S.J.,Moore, A.R.,Sudhamsu, J.,Chang, M.T.,Bae, I.,Dela Cruz, D.,Hunsaker, T.,Klijn, C.,Liau, N.P.D.,Lin, E.,Martin, S.E.,Modrusan, Z.,Piskol, R.,Segal, E.,Venkatanarayan, A.,Ye, X.,Yin, J.,Zhang, L.,Kim, J.S.,Lim, H.S.,Kim, K.P.,Kim, Y.J.,Han, H.S.,Lee, S.J.,Kim, S.T.,Jung, M.,Hong, Y.H.,Noh, Y.S.,Choi, M.,Han, O.,Nowicka, M.,Srinivasan, S.,Yan, Y.,Kim, T.W.,Malek, S.; ARAF mutations confer resistance to the RAF inhibitor belvarafenib in melanoma.; Nature, 594:418-423, 2021; PubMed: 33953400; DOI: 10.1038/s41586-021-03515-1

Experimental method

X-RAY DIFFRACTION (2 Å)